Introduction {#tca12300-sec-0005}
============

Thymic carcinoma is a rare thymic epithelial neoplasm with malignant cytologic features. According to the 2004 World Health Organization classification, the term "thymic carcinoma" was defined as all non‐organotypic malignant epithelial neoplasms other than germ cell tumors, which could be further classified into 13 distinct histological subtypes.[1](#tca12300-bib-0001){ref-type="ref"} Squamous cell carcinoma is the most common subtype, comprising more than 70% of all cases. It has an aggressive clinical course, tends to invade surrounding tissues, and metastasizes at an early stage.[2](#tca12300-bib-0002){ref-type="ref"}, [3](#tca12300-bib-0003){ref-type="ref"}, [4](#tca12300-bib-0004){ref-type="ref"} Therefore, systemic chemotherapy is critically important in the treatment of this disease. However, because this malignancy occurs infrequently, the optimal regimen has not been established. A few studies have reported promising results with anthracycline and cisplatin‐based chemotherapies.[5](#tca12300-bib-0005){ref-type="ref"}, [6](#tca12300-bib-0006){ref-type="ref"}, [7](#tca12300-bib-0007){ref-type="ref"} However, as anthracyclines are associated with severe myelosuppression and cardiac toxicity, investigation of less toxic non‐anthracycline regimens is needed.

With this in mind, we selected the combination of gemcitabine and cisplatin (GP) because gemcitabine has a mechanism of action that differs from older agents and this combination has a relatively low toxic profile. In addition, GP has shown promising efficacy in the treatment of other squamous cell carcinomas.[8](#tca12300-bib-0008){ref-type="ref"}, [9](#tca12300-bib-0009){ref-type="ref"}, [10](#tca12300-bib-0010){ref-type="ref"}, [11](#tca12300-bib-0011){ref-type="ref"}, [12](#tca12300-bib-0012){ref-type="ref"} The objective of this study was to retrospectively evaluate the efficacy and toxicity of the GP combination as first‐line chemotherapy against advanced thymic squamous cell carcinoma.

Methods {#tca12300-sec-0006}
=======

Patient population {#tca12300-sec-0007}
------------------

Between January 2003 and December 2012, 13 patients with previously untreated or unresectable recurrent thymic squamous cell carcinomas were analyzed. Written informed consent was obtained from all patients.

The pathological diagnosis of thymic squamous cell carcinoma was established according to histopathological criteria proposed by 2004 World Health Organization histologic classification and a pathologist reviewed and confirmed the diagnoses of all squamous cell carcinomas for this study.[1](#tca12300-bib-0001){ref-type="ref"} Histological samples were obtained by percutaneous computed tomography (CT)‐guided biopsy, video‐assisted thoracic surgery, cervical lymph node biopsy, or thymectomy. Patients\' histologic materials were, subsequently, reviewed by the same pathologist. Pretreatment evaluations consisted of medical histories, physical examinations, complete blood cell counts, biochemical examinations, thoracic and abdominal CT scans, and bone scans. Clinical stage was assessed according to criteria proposed by Masaoka *et al*.: stage IVa, pleural or pericardial dissemination; stage IVb, lymphogenous or hematogenous metastases.[13](#tca12300-bib-0013){ref-type="ref"} Performance status was assessed using Eastern Cooperative Oncology Group scales.

Treatment {#tca12300-sec-0008}
---------

All patients were intravenously treated with a combination of gemcitabine (1000 mg/m^2^, days 1 and 8) and cisplatin (75 mg/m^2^, administered over 3 continuous days) every three weeks, for at least two cycles. Dose reductions and dose interruptions were allowed as a result of toxicity. All patients were evaluated radiographically every two chemotherapy cycles to confirm treatment effectiveness or disease progression.

Evaluation of efficacy and study end points {#tca12300-sec-0009}
-------------------------------------------

The response to treatment was reassessed using Response Evaluation Criteria in Solid Tumors version 1.0. Overall survival (OS) was defined from the chemotherapy start date to death as a result of any cause. Progression‐free survival (PFS) was defined from the chemotherapy start date to first documented progression or death. Patients without documented progression were censored at the time of last disease assessment.

Safety profile {#tca12300-sec-0010}
--------------

Hematological and non‐hematological toxicities related to chemotherapy were graded according to Common Terminology Criteria for Adverse Events version 3.0.

Statistical methods {#tca12300-sec-0011}
-------------------

Statistical analysis was performed using SPSS Version19.0 (IBM Corp., Armonk, NY, USA). The Kaplan--Meier method was used to estimate median PFS, median OS, and one, three, and five‐year survival rates.

Results {#tca12300-sec-0012}
=======

Patient characteristics {#tca12300-sec-0013}
-----------------------

The characteristics of the 13 patients are summarized in Table [1](#tca12300-tbl-0001){ref-type="table-wrap"}. Seven patients were male, and six were female, with a median age of 53 years. The thymic lesions varied from roughly 3.0--10.5 cm at their greatest dimension, with an average size of 5.9 cm. Symptoms at diagnosis were cough, chest pain, shortness of breath, chest discomfort, and fatigue. Four patients were asymptomatic. No cases of myasthenia gravis or other associated symptomatic paraneoplastic syndromes were observed. All patients showed a good performance status of 0 or 1. According to the Masaoka staging system, three patients were in stage IVa and 10 were in stage IVb. The metastatic sites, in sequence, were the lungs, pleura, lymph nodes (diaphragm and supraclavicular), bones, and liver. Nine patients were untreated; four had unresectable recurrent disease after prior surgery and radiotherapy, and two of these patients had received prior adjuvant chemotherapy (taxanes plus platinum regimen).

###### 

Clinical findings in 13 cases of thymic squamous cell carcinoma

  -----------------------------------------------------------------------------------------------------------
  Case   Age\            Stage   Timing of CT   No. of cycles   Response   PFS (months)   Outcomes (months)
         (year)/gender                                                                    
  ------ --------------- ------- -------------- --------------- ---------- -------------- -------------------
   1     23/F            IVb     Untreated      4               PR         11.9           66.7, died

   2     58/M            IVb     Untreated      4               SD         14.5           56.1, died

   3     33/F            IVa     Untreated      5               PR         38.9           38.9, alive

   4     60/F            IVb     Untreated      3               SD         45.7           63.4, alive

   5     62/M            IVb     Untreated      4               PR         11.3           32.6, died

   6     48/F            IVb     Untreated      8               PR         20.3           50.7, died

   7     59/F            IVb     Untreated      8               PR         17.1           27.2, died

   8     56/M            IVb     Untreated      4               SD         5.5            5.5,died of CHD

   9     41/M            IVa     Recurrence     2               PD         1.8            9.8, died

  10     46/M            IVb     Recurrence     4               PR         7.3            39.8, alive

  11     59/M            IVb     Recurrence     4               PR         7.7            25.4, alive

  12     37/F            IVa     Untreated      4               PR         20.7           21.9, alive

  13     53/M            IVb     Recurrence     6               SD         8.0            26.2, alive
  -----------------------------------------------------------------------------------------------------------

CHD, coronary heart disease; CT, chemotherapy; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease.
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Treatment efficacy {#tca12300-sec-0014}
------------------

A total of 60 cycles were administered, with a median number of four cycles per patient. One patient had a dose reduction, while in another carboplatin was substituted for cisplatin as a result of Grade 3 vomiting.

There were no complete responders. Eight patients achieved a partial response, four patients had stable disease, and one had progressive disease (PD). The overall response rate (ORR) and disease control rate (DCR) were 61.5% and 92.3%, respectively. En bloc extended total thymectomy was performed in the three patients with stage IVa disease after chemotherapy. Thoracic radiotherapy was carried out before disease progression in six patients with a total dose of 50Gy--64Gy. Only one patient remained disease‐free for 39 months. One patient died of coronary heart disease without tumor progression. The other 11 patients received second‐line chemotherapy when their disease progressed, including seven patients who received further lines of chemotherapy. Chemotherapeutic drugs included carboplatin, paclitaxel, S‐1, nedaplatin, irinotecan, nab‐paclitaxel, docetaxel, and ifosphamide and bevacizumab, used alone or in combination.

Six patients died of the disease and one non‐thymic carcinoma‐related death was observed. The median PFS was 14.5 months (95% confidence interval \[CI\], 9.2--19.8 months) and the median OS was 50.7 months (95% CI, 24.9--76.5 months). The PFS and OS curves are shown in Figure [1](#tca12300-fig-0001){ref-type="fig"}. The one, three and five‐year survival rates were 84.6%, 63.5%, and 31.7%, respectively.

![(a) Progression‐free survival curve for 13 patients with advanced thymic squamous cell carcinoma. (b) Overall survival curve for 13 patients with advanced thymic squamous cell carcinoma.](TCA-7-167-g001){#tca12300-fig-0001}

Safety profile {#tca12300-sec-0015}
--------------

The main chemotherapy toxicities of the 13 patients are summarized in Table [2](#tca12300-tbl-0002){ref-type="table-wrap"}. The principal toxicity was hematological. Grade 4 thrombocytopenia and neutropenia were observed in one and two patients, respectively. None of the patients developed febrile neutropenia. Only one patient required platelet transfusions. In addition, Grade 3 thrombocytopenia was observed in one patient, anemia in one, and neutropenia in four patients. Six patients required granulocyte colony stimulating factor support. Non‐hematological toxicities included vomiting, elevated alanine aminotransferase, sensory neuropathy, rash, and fever, but were generally low and tolerable. There was no occurrence of nephrotoxicity or toxic death.

###### 

Hematological and non‐hematological toxicities

  n=13                 Grade≤2     Grade≥3
  -------------------- ----------- -----------
  Hemotological                    
  Leukocytopenia       9 (69.2%)   4 (30.8%)
  Neutropenia          5 (38.5%)   6 (46.2%)
  Anemia               4 (30.8%)   1 (7.7%)
  Thrombocytopenia     3 (23.1%)   2 (15.4%)
  Non‐hematological                
  Fever                3 (23.1%)   0 (0%)
  Vomiting             9 (69.2%)   1 (7.7%)
  ALT increased        3 (23.1%)   0 (0%)
  Sensory neuropathy   9 (69.2%)   0 (0%)
  Rash                 3 (23.1%)   0 (0%)

ALT, alanine aminotransferase.
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Discussion {#tca12300-sec-0016}
==========

Thymic carcinoma represents a heterogeneous group of tumors with a wide morphologic and behavioral spectrum. Most of the previous studies have included all of the subtypes, obscuring distinct clinicopathological features and confusing treatment results; therefore, we solely addressed thymic squamous cell carcinoma. Our results indicate that thymic squamous cell carcinoma diagnosis occurs at a peak age of 50--60, with a slight male predominance. The median size of tumors in this study was 5.9 cm, and most of the patients presented symptoms. Our findings are similar to those of Zhao *et al*.[14](#tca12300-bib-0014){ref-type="ref"} None of the patients in our study experienced symptoms of myasthenia gravis or other associated symptomatic paraneoplastic syndromes. Previous studies have reported that thymic squamous cell carcinoma rarely occurs with myasthenia gravis.[15](#tca12300-bib-0015){ref-type="ref"}, [16](#tca12300-bib-0016){ref-type="ref"}

Chemotherapy is commonly administered to patients with unresectable and/or metastatic thymic squamous cell carcinoma. Standard systemic chemotherapy for advanced thymic carcinoma has not been determined because of its rarity. In general, the combination chemotherapy regimens most widely evaluated have combined platinum analogs, anthracyclines and other agents (Table [3](#tca12300-tbl-0003){ref-type="table-wrap"}). For first‐line regimens, response rates range from 22--75% with median OS ranging from 19--49 months. Anthracycline‐based regimens, such as CODE (cisplatin, vincristine, doxorubicin, etoposide) and ADOC (cisplatin, doxorubin, vincristine and cyclophosphamide), have, to date, been widely used; however, as toxicity is associated with their use, an alternative treatment needs to be found. Platinum‐based chemotherapy is another choice for advanced thymic carcinoma. Despite the relatively short median PFS/time to progression reported, there is a frustrating lack of data to guide use of second‐line cytotoxic therapies for treatment of patients with thymic carcinoma. Okuma *et al*. reported ORRs of first, second, third, and fourth‐line chemotherapy of 60.9%, 39.1%, 23.1%, and 25.0%, respectively.[25](#tca12300-bib-0025){ref-type="ref"} Although the role of salvage chemotherapy remains uncertain in thymic carcinoma, we consider that beneficial salvage chemotherapy may contribute to better outcomes in certain patients.

###### 

Series of patients with thymic carcinoma treated with cytotoxic chemotherapy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chemotherapeutic regimen                            Years   Treatment line   Prospective or retrospective   No. of patients   ORR%   Median PFS/TTP\   Median OS\
                                                                                                                                       (months)          (months)
  --------------------------------------------------- ------- ---------------- ------------------------------ ----------------- ------ ----------------- ------------
  ADOC[6](#tca12300-bib-0006){ref-type="ref"}         2002    First            P                              8                 75%    NA                19

  CODE[17](#tca12300-bib-0017){ref-type="ref"}        2003    First            R                              12                42%    6                 46

  VIP[18](#tca12300-bib-0018){ref-type="ref"}         2008    First            R                              9                 44%    NA                20

  PC[19](#tca12300-bib-0019){ref-type="ref"}          2010    First            P                              11                36%    8                 23

  PC[20](#tca12300-bib-0020){ref-type="ref"}          2011    First            P                              23                22%    5                 20

  ADOC/ADOCb[7](#tca12300-bib-0007){ref-type="ref"}   2011    First            R                              34                50%    8                 21

  IP[21](#tca12300-bib-0021){ref-type="ref"}          2011    First            R                              9                 56%    8                 34

  PC[22](#tca12300-bib-0022){ref-type="ref"}          2011    First            R                              16                38%    9                 49

  IP[23](#tca12300-bib-0023){ref-type="ref"}          2007    Second           R                              7                 29%    NA                18

  PC[24](#tca12300-bib-0024){ref-type="ref"}          2014    Second           R                              12                25%    3.5               24
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADOC, doxorubicin, cyclophosphamide, vincristine, cisplatin; ADOCb, doxorubicin, cyclophosphamide, vincristine, carboplatin; CODE, cisplatin, vincristine, doxorubicin, etoposide; IP, irinotecan,cisplatin; NA, not available; OS, overall survival; PC, paclitaxel,carboplatin; PFS, progression‐free survival; TTP, time to progression; VIP, etoposide, ifosfamide, cisplatin.
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Gemcitabine and cisplatin chemotherapy is one of many standard regimens for several malignancies and has prominent efficacy, especially in patients with squamous cell cancers.[8](#tca12300-bib-0008){ref-type="ref"}, [9](#tca12300-bib-0009){ref-type="ref"}, [10](#tca12300-bib-0010){ref-type="ref"}, [11](#tca12300-bib-0011){ref-type="ref"}, [12](#tca12300-bib-0012){ref-type="ref"} Compared with pemetrexed plus cisplatin, GP showed even better efficacy in patients with squamous cell lung cancer.[12](#tca12300-bib-0012){ref-type="ref"} Thus, we speculate that GP may be a potential regimen in advanced thymic squamous cell carcinoma.

In this trial, the GP regimen resulted in an ORR of 61.5% and DCR of 92.3% in patients with untreated or recurrent advanced thymic squamous cell carcinoma. Median PFS and median OS were 14.5 (95% CI, 9.2--19.8 months) and 50.7 months (95% CI, 24.9--76.5 months), respectively. Our results are similar to those observed with previously reported cisplatin and/or doxorubicin‐based regimens, and better than those observed with a paclitaxel and carboplatin regimen, while our PFS and OS rates were superior.[6](#tca12300-bib-0006){ref-type="ref"}, [7](#tca12300-bib-0007){ref-type="ref"}, [17](#tca12300-bib-0017){ref-type="ref"}, [18](#tca12300-bib-0018){ref-type="ref"}, [19](#tca12300-bib-0019){ref-type="ref"}, [20](#tca12300-bib-0020){ref-type="ref"}, [21](#tca12300-bib-0021){ref-type="ref"}, [22](#tca12300-bib-0022){ref-type="ref"} This may be explained, at least in part, by the relatively slow growth characteristics of thymic squamous cell carcinoma.^14^ It may also be attributable to the local therapies administered before progression, and the fact that all of the patients received subsequent chemotherapy when their disease progressed.

As we perform routine blood tests in our clinical practice, relatively complete evaluations of hematological toxicity incidences were recorded. Grade 3/4 myelosuppression was seen in seven (53.8%) patients. However, because of the retrospective design of this study, non‐hematological toxicity data, especially for low‐grade toxicities, could not be completely evaluated. Despite the existence of one patient with grade 3 chemotherapy‐induced vomiting, the incidence of high grade vomiting and nephrotoxicity may be lower in our study than in previous reports.[8](#tca12300-bib-0008){ref-type="ref"}, [9](#tca12300-bib-0009){ref-type="ref"}, [12](#tca12300-bib-0012){ref-type="ref"} The differences in gastrointestinal toxicities might be a result of the use of cisplatin, which is usually given over three continuous days in Asia in order to decrease nephrotoxicity and vomiting. In this study, although myelosuppression was the most common adverse event, there was no febrile neutropenia, only one patient needed platelet transfusions, and there were no treatment‐related deaths. This combination chemotherapy, thus, provided acceptable results with respect to toxicity.

Limitations of the present study include its retrospective nature and the small sample size, but it is difficult to develop a large, prospective clinical study for such a rare malignancy.

Conclusion {#tca12300-sec-0017}
==========

Our treatment results suggest that gemcitabine may be a novel and reasonable alternative agent for advanced thymic squamous cell carcinoma, especially in patients who cannot tolerate anthracyclines. GP is active against advanced thymic squamous cell carcinoma, with manageable toxicity.
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